BNTX Valuation
Biontech SE
$
100.000
- Overview
- Forecast
- Valuation
- Earnings
BNTX Relative Valuation
BNTX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BNTX is overvalued; if below, it's undervalued.
Historical Valuation
Biontech SE (BNTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.53 is considered Undervalued compared with the five-year average of -4.04. The fair price of Biontech SE (BNTX) is between 139.27 to 190.20 according to relative valuation methord. Compared to the current price of 100.00 USD , Biontech SE is Undervalued By 28.2%.
Relative Value
Fair Zone
139.27-190.20
Current Price：100.00
28.2%
Undervalued
-16.52
PE
1Y
3Y
5Y
Trailing
Forward
-6.11
EV/EBITDA
Biontech SE. (BNTX) has a current EV/EBITDA of -6.11. The 5-year average EV/EBITDA is 3.56. The thresholds are as follows: Strongly Undervalued below -15.65, Undervalued between -15.65 and -6.04, Fairly Valued between 13.16 and -6.04, Overvalued between 13.16 and 22.77, and Strongly Overvalued above 22.77. The current Forward EV/EBITDA of -6.11 falls within the Undervalued range.
-4.21
EV/EBIT
Biontech SE. (BNTX) has a current EV/EBIT of -4.21. The 5-year average EV/EBIT is 1.13. The thresholds are as follows: Strongly Undervalued below -27.29, Undervalued between -27.29 and -13.08, Fairly Valued between 15.33 and -13.08, Overvalued between 15.33 and 29.54, and Strongly Overvalued above 29.54. The current Forward EV/EBIT of -4.21 falls within the Historic Trend Line -Fairly Valued range.
8.53
PS
Biontech SE. (BNTX) has a current PS of 8.53. The 5-year average PS is 5.74. The thresholds are as follows: Strongly Undervalued below 0.31, Undervalued between 0.31 and 3.02, Fairly Valued between 8.46 and 3.02, Overvalued between 8.46 and 11.17, and Strongly Overvalued above 11.17. The current Forward PS of 8.53 falls within the Overvalued range.
-33.84
P/OCF
Biontech SE. (BNTX) has a current P/OCF of -33.84. The 5-year average P/OCF is 4.25. The thresholds are as follows: Strongly Undervalued below -98.00, Undervalued between -98.00 and -46.87, Fairly Valued between 55.38 and -46.87, Overvalued between 55.38 and 106.51, and Strongly Overvalued above 106.51. The current Forward P/OCF of -33.84 falls within the Historic Trend Line -Fairly Valued range.
-22.36
P/FCF
Biontech SE. (BNTX) has a current P/FCF of -22.36. The 5-year average P/FCF is -8.08. The thresholds are as follows: Strongly Undervalued below -120.50, Undervalued between -120.50 and -64.29, Fairly Valued between 48.13 and -64.29, Overvalued between 48.13 and 104.34, and Strongly Overvalued above 104.34. The current Forward P/FCF of -22.36 falls within the Historic Trend Line -Fairly Valued range.
Biontech SE (BNTX) has a current Price-to-Book (P/B) ratio of 1.11. Compared to its 3-year average P/B ratio of 1.29 , the current P/B ratio is approximately -14.09% higher. Relative to its 5-year average P/B ratio of 5.01, the current P/B ratio is about -77.82% higher. Biontech SE (BNTX) has a Forward Free Cash Flow (FCF) yield of approximately -9.31%. Compared to its 3-year average FCF yield of 20.99%, the current FCF yield is approximately -144.34% lower. Relative to its 5-year average FCF yield of 14.05% , the current FCF yield is about -166.22% lower.
1.11
P/B
Median3y
1.29
Median5y
5.01
-9.31
FCF Yield
Median3y
20.99
Median5y
14.05
Competitors Valuation Multiple
The average P/S ratio for BNTX's competitors is 41.14, providing a benchmark for relative valuation. Biontech SE Corp (BNTX) exhibits a P/S ratio of 8.53, which is -79.26% above the industry average. Given its robust revenue growth of 102.64%, this premium appears sustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BNTX increased by 13.35% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 128.70M to 260.80M.
The secondary factor is the P/E Change, contributed -12.91%to the performance.
Overall, the performance of BNTX in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
HAL
Halliburton Co
22.730
USD
+0.44%
DOV
Dover Corp
178.860
USD
-1.50%
LPLA
LPL Financial Holdings Inc
364.480
USD
-0.10%
WPM
Wheaton Precious Metals Corp
100.420
USD
+3.28%
CPAY
Corpay Inc
325.670
USD
+0.15%
ITUB
Itau Unibanco Holding SA
7.140
USD
+0.42%
CHD
Church & Dwight Co Inc
93.160
USD
+1.16%
EQR
Equity Residential
66.120
USD
+1.27%
IOT
Samsara Inc
36.140
USD
-0.85%
SYF
Synchrony Financial
76.340
USD
-0.31%
FAQ
Is Biontech SE (BNTX) currently overvalued or undervalued?
Biontech SE (BNTX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 8.53 is considered Undervalued compared with the five-year average of -4.04. The fair price of Biontech SE (BNTX) is between 139.27 to 190.20 according to relative valuation methord. Compared to the current price of 100.00 USD , Biontech SE is Undervalued By 28.20% .
What is Biontech SE (BNTX) fair value?
How does BNTX's valuation metrics compare to the industry average?
What is the current P/B ratio for Biontech SE (BNTX) as of Aug 30 2025?
What is the current FCF Yield for Biontech SE (BNTX) as of Aug 30 2025?
What is the current Forward P/E ratio for Biontech SE (BNTX) as of Aug 30 2025?